[DE] THROMBININHIBITOREN<br/>[EN] THROMBIN INHIBITORS<br/>[FR] INHIBITEURS DE LA THROMBINE
申请人:BASF AKTIENGESELLSCHAFT
公开号:WO1999037668A1
公开(公告)日:1999-07-29
(DE) Es werden Verbindungen der Formel A-B-D-E-F, worin A, B, D, E und F die in der Beschreibung angegebene Bedeutung besitzen, und deren Herstellung beschrieben. Die neuen Verbindungen eignen sich zur Herstellung von Medikamenten.(EN) The invention relates to compounds of the formula A-B-D-E-F, in which A, B, D, E and F have the meanings given in the description, and to their production. These new compounds are suitable for producing medicines.(FR) L'invention concerne des composés de formule A-B-D-E-F, dans laquelle A, B, D, E et F ont la signification mentionnée dans la description, ainsi que leur procédé de fabrication. Ces nouveaux composés sont utiles pour la préparation de médicaments.
这种化合物涉及分子式为 A-B-D-E-F 的结构,其中 A、B、D、E 和 F 的含义在说明中给出,以及它们的生产过程。这些新的化合物可用于 制药。
THROMBININHIBITOREN
申请人:BASF AKTIENGESELLSCHAFT
公开号:EP1051431A1
公开(公告)日:2000-11-15
PRODRUGS VON THROMBININHIBITOREN
申请人:BASF AKTIENGESELLSCHAFT
公开号:EP1165601A2
公开(公告)日:2002-01-02
NEW DERIVATIVES OF CYANO-ARYL (OR CYANOHETEROARYL)-CARBONYL-PIPERAZINYL-PYRIMIDINES, THEIR PREPARATION AND APPLICATION AS MEDICATION
申请人:LABORATORIOS DEL DR. ESTEVE, S.A.
公开号:EP1327630B1
公开(公告)日:2007-12-12
TOLUIDINE SULFONAMIDES AND THEIR USE
申请人:Alonson Jorge
公开号:US20120095012A1
公开(公告)日:2012-04-19
The present invention provides compounds of formula (I), wherein R
1
is a monocyclic 5- or 6-membered heteroaryl; R
4
is phenyl or monocyclic 5- or 6-membered heteroaryl; and the other substituents as defined in the claims, that inhibit cell and cell division and that inhibit the activation of Hypoxia Inducible Factor (HIF)—mediated transcription and signaling under hypoxic conditions. In one aspect, the compounds of the present invention are useful for the preparation of a medicament for the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularisation. Also provided is a pharmaceutical composition, comprising a compound of the invention and a second therapeutic agent or radiation, useful for the treatment or prevention of the mentioned diseases or disorders.